ย้ถนำฐา๔

์•ฝํ•™๋Œถฤว๊™

๋ชจ๋ฐ”์ผ ๋ฉ”๋‰ด ์—ด๊ธฐ
 

"์›”๋“œ ํด๋ž˜์Šค ์•ฝํ•™๋Œถฤว๊™"์„ ์ง€ํ–ฅํ•˜๋Š”
์•ัซฃผ๋Œถฤว๊™๊ต ์•ฝํ•™๋Œถฤว๊™

์•ฝ๋Œ€์†Œ์‹

์•ฝํ•™๋Œถฤว๊™ ์ด๋ฒ”์ง„๊ต์ˆ˜ ์—ฐ๊ตฌํŒ€, ์งถฤ๋ฐฉ์‚ฐ์‚ฌ์Šฌ๊ธธ์ด ์ด์šฉ ์•”์„ธํฌํƒ€๊ฒŸํŒ… ์›๋ฆฌ ๊ทœ๋ช…

 


 ์•ัซฃผ๋Œถฤว๊™๊ต ์•ฝํ•™๋Œถฤว๊™ ์ด๋ฒ”์ง„ ๊ต์ˆ˜ ์—ฐ๊ตฌํŒ€์ด ์‚ฌ์Šฌ๊ธธ์ด๊ฐ€ ๋‹ค๋ฅธ ์งถฤ๋ฐฉ์‚ฐ์„ ์•Œ๋ถ€๋ฏผ์— ๊ฒฐํ•ฉ์‹œํ‚จ ๋‚˜๋…ธ์ „๋‹ฌ์ฒด๋ฅผ ์‚ฌ์šฉํ•˜์—ฌ ์•”์„ธํฌ์˜ ์œ ๋ฆฌ์งถฤ๋ฐฉ์‚ฐ์ˆ˜์šฉ์ฒด(FFARs)์™€์˜ ์ƒํ˜ธ์ž‘์šฉ์„ ๊ทน๋Œ€ํ™”ํ•จ์œผ๋กœ์จ ์•”์„ธํฌ์น˜๋ฃŒ ํšจ๋Šฅ์„ ์ตœ์ ํ™”ํ•˜๋Š” ์›๋ฆฌ๋ฅผ ๊ทœ๋ช…ํ•˜์—ฌ ์•ฝํ•™ ๋ฐ ์•ฝ๋ฌผํ•™ ๋ถ„์•ผ(Pharmacy&Pharmacology) ์ƒ์œ„ 3%์ธ Journal of Controlled Release์— ๊ฒŒ์žฌํ–ˆ๋‹ค. ๋…ผ๋ฌธ์ œ๋ชฉ์€ ์ธ๊ฐ„ ๊ฒฐ์žฅ ์ง์žฅ์•” ์ด์ข… ์ด์‹ ๋งˆ์šฐ์Šค๋ชจ๋ธ์—์„œ ํŒจํ‹ฐ๊ฒŒ์ด์…˜ ํ”Œ๋žซํผ ์•Œ๋ถ€๋ฏผ ๋‚˜๋…ธ์ž…์ž์˜ ์‹œํ—˜๊ด€๋‚ด ๋ฐ ์ƒ์ฒด๋‚ด ํ•ญ์•”ํ™œ์„ฑ์— ๋Œ€ํ•œ ์งถฤ๋ฐฉ์‚ฐ ์‚ฌ์Šฌ ๊ธธ์ด์˜ ์ค‘์š”์„ฑ(Importance of the fatty acid chain length on in vitro and in vivo anticancer activity of fattigation-platform albumin nanoparticles in human colorectal cancer xenograft mice model)์ด๋‹ค.

 

์—ฐ๊ตฌ์˜ ๋ชฉํ‘œ๋Š” ์„œ๋กœ ๋‹ค๋ฅธ ์‚ฌ์Šฌ ๊ธธ์ด ์งถฤ๋ฐฉ์‚ฐ-์ ‘ํ•ฉ๋œ ์•Œ๋ถ€๋ฏผ ๋‚˜๋…ธ ์ž…์ž (ANP)๋ฅผ ์„ค๊ณ„ํ•˜๊ณ  ์œ ๋ฆฌ์งถฤ๋ฐฉ์‚ฐ์ˆ˜์šฉ์ฒด(FFAR) ๊ณผ๋ฐœํ˜„ ์„ธํฌ์™€ HCT116 ์ธ๊ฐ„ ๊ฒฐ์žฅ ์ง์žฅ์•” ์ด์ข… ์ด์‹ ๋งˆ์šฐ์Šค ๋ชจ๋ธ์—์„œ ํ•ญ์•” ํ™œ์„ฑ์„ ํ‰๊ฐ€ํ•˜๋Š” ๊ฒƒ์ด์—ˆ๋‹ค. ์งถฤ๋ฐฉ์‚ฐ-์•Œ๋ถ€๋ฏผ ์ ‘ํ•ฉ์ฒด์—์„œ ๊ธธ์ด๊ฐ€ ๋‹ค๋ฅธ ์‚ฌ์Šฌ ๊ธธ์ด์˜ ์งถฤ๋ฐฉ์‚ฐ (๋ถถฤํ‹ฐ๋ฅด์‚ฐ; C4 ๋ฐ ์Šคํ…Œ์•„๋ฅด ์‚ฐ; C18)์ด ํฌ์ ‘๋œ ๋‚˜๋…ธ์ž…์ž๋Š” ์ž๊ฐ€๋‚˜๋…ธ ํŠน์„ฑ๊ณผ ์€ ์ƒ์ดํ•œ ๋ฌผ๋ฆฌ ํ™”ํ•™์  ํŠน์„ฑ ๋ฐ ํ•ญ์•” ํ™œ์„ฑ์„ ๋‚˜ํƒ€๋ƒˆ๋‹ค. ํŠนํžˆ ํ•ญ์•”์ œ์ธ ๋…์†Œ๋ฃจ๋น„


์‹ ์„ ํ•จ์œ ํ•˜๋Š” ์žฅ์‡„์งถฤ๋ฐฉ์‚ฐ์ ‘ํ•ฉ ๋‚˜๋…ธ์ž…์ž๋Š” HCT116 ์ธ๊ฐ„๊ฒฐ์žฅ์ง์žฅ์•” ์ด์ข…์ด์‹๋งˆ์šฐ์Šค ๋ชจ๋ธ์—์„œ ์œ ๋ฆฌ์งถฤ๋ฐฉ์‚ฐ์ˆ˜์šฉ์ฒด(FFAR)์™€์˜ ์ƒํ˜ธ ์ž‘์šฉ์„ ์ƒ์Šน์ ์œผ๋กœ ํ™œ์„ฑํ™”์‹œ์ผœ, ์งถฤ๋ฐฉ์‚ฐ์„ ํฌ์ ‘ํ•˜์ง€ ์•Š์€ ๋‚˜๋…ธ์ž…์ž๋‚˜ ๋‹จ์‡„์งถฤ๋ฐฉ์‚ฐ ์ฒ˜๋ฆฌ๊ตฌ๋ฃน์— ๋น„ํ•˜์—ฌ ๊ฐœ์„ ๋œ ํ•ญ์•” ํ™œ์„ฑ ๋ฐ ๊ฐ์†Œ ๋œ ๋ถ€์ž‘์šฉ์„ ๋‚˜ํƒ€๋ƒ„์„ ํ™•์ธํ•˜์˜€๋‹ค. ๋‹ค์–‘ํ•œ ์งถฤ๋ฐฉ์‚ฐ์„ ๊ฑฐ๋Œ€๋ถ„์ž์— ํฌ์ ‘์‹œํ‚ค๋Š” Fattigation platform ๊ธฐ์ˆ ์€ ๋ณธ ์—ฐ๊ตฌ์ง„๋“ค์˜ ๋…์ฐฝ์ ์ธ ๋ถ„์•ผ๋กœ ํ–ฅํ›„ ์‚ฌ์Šฌ ๊ธธ์ด๊ฐ€ ๋‹ค๋ฅธ ๋‹ค์–‘ํ•œ ์งถฤ๋ฐฉ์‚ฐ์„ ์ด์šฉํ•˜์—ฌ ๋‹ค์–‘ํ•œ ์•”์น˜๋ฃŒ ํ‘œ์ ํ™”์™€ ๋‚œ์šฉ์„ฑ์•ฝ๋ฌผ๋“ค์˜ ๊ฐ€์šฉํ™” ๋“ฑ ์ƒˆ๋กœ์šด ์•ฝ๋ฌผ์ „๋‹ฌ์‹œ์Šคํ…œ์— ํ™œ์šฉ๋  ๊ฒƒ์œผ๋กœ ๊ธฐ๋Œ€ํ•œ๋‹ค.